TCW Group’s Acadia Pharmaceuticals ACAD Stock Holding History

TCW Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,450	Closed	-$270K	–	336
2021 Q1	$270K	Sell	10,450 -76	-0.7%	-$3.35K	﹤0.01%	326
2020 Q4	$563K	Buy	+10,526	New	+$523K	﹤0.01%	310

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

TCW Group's ACAD Position: Q2 2021 in Review

TCW Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 10,450 shares — an estimated $270K sold.

TCW Group first reported a position in ACAD in Q4 2020 and held it in 2 quarters. The position peaked at $563K in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

TCW Group reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
TCW Group sold 10,450 Acadia Pharmaceuticals shares in Q2 2021, an estimated $270K.
TCW Group first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 2 quarters.
TCW Group's Acadia Pharmaceuticals position peaked at $563K in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on TCW Group's 13F filing for Q2 2021, filed 23 Jul 2021.